Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG loxenatide vs linagliptin for cardiac microangiopathy in type 2 diabetes with macroalbuminuria
ChiCTR2100049856Phase 4Not yet recruiting
- Sponsor
- Zhu Xianyi Memorial Hospital
- Start
- Aug 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of polyethylene glycol loxenatide in type 2 diabetes mellitus (T2DM), diabetic glomerulosclerosis, Coronary Small Vessel Disease (CMD) and 1 more (2 arms), sponsored by Zhu Xianyi Memorial Hospital. Primary endpoints: Cardiac magnetic resonance imaging, 24-hour Holter monitoring and 1 more. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
polyethylene glycol loxenatide
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosisCoronary Small Vessel Disease (CMD)diabetic retinopathy (DR)
Beyond the preview
Go deeper on ChiCTR2100049856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049856.